1,889 Shares in Natera, Inc. $NTRA Acquired by Chicago Partners Investment Group LLC

Key Points

• Chicago Partners Investment Group LLC acquired 1,889 shares of Natera, Inc., valued at approximately $319,000, signaling growing institutional interest in the medical research company.
• Natera reported a quarterly revenue of $546.60 million, exceeding consensus estimates, despite missing earnings per share targets and having a negative net margin of 12.89%.
• Analysts have a consensus rating of "Moderate Buy" for Natera, with a consensus price target of $197.59, reflecting optimism about the company's performance and growth potential.

Chicago Partners Investment Group LLC acquired a new position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 1,889 shares of the medical research company's stock, valued at approximately $319,000.

Other institutional investors have also added to or reduced their stakes in the company. Bank of Jackson Hole Trust acquired a new position in Natera during the 1st quarter worth approximately $29,000. Hilltop National Bank acquired a new position in Natera during the 2nd quarter worth approximately $33,000. Oliver Lagore Vanvalin Investment Group acquired a new position in Natera during the 2nd quarter worth approximately $36,000. TCTC Holdings LLC increased its position in Natera by 114.8% during the 1st quarter. TCTC Holdings LLC now owns 232 shares of the medical research company's stock worth $33,000 after purchasing an additional 124 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. increased its position in Natera by 83.5% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company's stock worth $33,000 after purchasing an additional 106 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Stock Performance

NASDAQ:NTRA opened at $195.00 on Friday. The firm's fifty day moving average is $170.70 and its 200-day moving average is $159.76. Natera, Inc. has a 52 week low of $117.27 and a 52 week high of $196.63. The firm has a market cap of $26.76 billion, a P/E ratio of -102.09 and a beta of 1.74.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The firm had revenue of $546.60 million during the quarter, compared to the consensus estimate of $476.84 million. During the same period in the prior year, the company posted ($0.30) earnings per share. The company's revenue for the quarter was up 32.2% compared to the same quarter last year. Natera has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Insider Activity

In related news, CFO Michael Burkes Brophy sold 602 shares of the business's stock in a transaction on Tuesday, October 21st. The shares were sold at an average price of $187.95, for a total transaction of $113,145.90. Following the transaction, the chief financial officer owned 70,109 shares in the company, valued at $13,176,986.55. The trade was a 0.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Steven Leonard Chapman sold 1,603 shares of the business's stock in a transaction on Tuesday, October 21st. The shares were sold at an average price of $187.95, for a total transaction of $301,283.85. Following the transaction, the chief executive officer owned 155,855 shares in the company, valued at $29,292,947.25. The trade was a 1.02% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 70,276 shares of company stock valued at $10,794,948. Company insiders own 5.63% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Barclays reiterated an "overweight" rating and set a $210.00 price objective (up from $190.00) on shares of Natera in a research report on Friday, August 8th. Evercore ISI raised shares of Natera to a "strong-buy" rating and set a $170.00 target price on the stock in a report on Monday, July 28th. Wells Fargo & Company assumed coverage on shares of Natera in a report on Monday, September 22nd. They set an "equal weight" rating and a $175.00 target price on the stock. Morgan Stanley reissued an "overweight" rating and set a $195.00 target price on shares of Natera in a report on Sunday, August 10th. Finally, Cowen reissued a "buy" rating on shares of Natera in a report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $197.59.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.